Talis Biomedical Corp (TLIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,831 | -113,012 | -86,083 | -60,062 | -33,051 |
| Depreciation Amortization | 174 | 8,830 | 5,268 | 1,343 | 363 |
| Accounts receivable | 182 | -125 | -250 | -453 | -2,417 |
| Accounts payable and accrued liabilities | -148 | -1,194 | -1,009 | -1,144 | 141 |
| Other Working Capital | -776 | -7,686 | -11,817 | -10,850 | -13,024 |
| Other Operating Activity | 1,934 | 13,051 | 7,298 | 5,395 | 4,230 |
| Operating Cash Flow | $-16,465 | $-100,136 | $-86,593 | $-65,771 | $-43,758 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -24 | -1,615 | -1,566 | -706 | -507 |
| Investing Cash Flow | $-24 | $-1,615 | $-1,566 | $-706 | $-507 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 33 | 406 | 406 | 314 | 314 |
| Financing Cash Flow | $33 | $406 | $406 | $314 | $314 |
| Beginning Cash Position | 131,967 | 233,312 | 233,312 | 233,312 | 233,312 |
| End Cash Position | 115,511 | 131,967 | 145,559 | 167,149 | 189,361 |
| Net Cash Flow | $-16,456 | $-101,345 | $-87,753 | $-66,163 | $-43,951 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,465 | -100,136 | -86,593 | -65,771 | -43,758 |
| Capital Expenditure | -24 | -1,615 | -1,566 | -706 | -507 |
| Free Cash Flow | -16,489 | -101,751 | -88,159 | -66,477 | -44,265 |